Quality of life and economic evaluation in SLE clinical trials

Lupus

Volumn 8, Issue 8, 1999, Pages 645-654

  Gordon, Caroline ^c   Clarke, Ann E ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c NONE

Author keywords

Direct medical costs; Health status; Indirect costs; Quality of life; Systemic lupus erythematosus

Indexed keywords

DISEASE ACTIVITY; ECONOMIC EVALUATION; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANXIETY; CANADA; CLINICAL TRIALS; COSTS AND COST ANALYSIS; DEPRESSION; EUROPE; FATIGUE; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 0032758602     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399680411344     Document Type: Review

References (85)

1. Gladman DD, Goldsmith CH, Urowitz MB et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994; 21: 1468-1471.
2. Urowitz MB, Gladman DD. Measures of disease activity and damage in SLE. Baillieres Clin Rheumatol 1998; 12: 405-413.
3. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
4. Wolfe F. Health-status questionnaires. Rheum Dis Clin North Am 1995; 21: 445-464.
5. Gladman D, Urowitz M, Fortin P et al. Systemic lupus international collaborating clinics conference on assessment of lupus flare and quality of life measures in SLE. J Rheumatol 1996; 23: 1953-1955.
6. Isenberg D, Gladman D. Assessing lupus [letter]. Arthritis Rheum 1998; 41: 2276
7. Strand V, Gladman D, Isenberg D et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999; 26: 490-497.
8. Smolen JS, Strand V, Cardiel M et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 1999; 26: 504-507.
9. Clarke AE, Esdaile JM, Bloch DA et al. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993; 36: 1548-1549.
10. Karlson EW, Daltroy LH, Lew RA et al. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 47-56.
11. Dobkin PL, Fortin PR, Joseph L et al. Psychosocial contributors to mental and physical health in patients with systemic lupus erythematosus. Arthritis Care Res 1998; 11: 23-31.
12. DaCosta D, Dobkin PL, Pinard L et al. The role of stress in functional disability among women with systemic lupus erythematosus: a prospective study. Arthritis Care Res 1999; 12: 112-119.
13. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford University Press; New York 1996.
14. Russell LB, Gold MR, Siegel JE et al The role of cost-effectiveness analysis in health and medicine. JAMA 1996; 276: 1172-1177.
15. Weinstein MC, Siegel JE, Gold MR et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-1258.
16. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations fo reporting cost-effectiveness analyses. JAMA 1996; 276: 1339-1341.
17. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q 1982; 60: 429-462.
18. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 1990; 6: 57-75.
19. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford 1987.
20. Sloan FA (ed). Valuing Health Care: Costs, Benefits and Effectiveness of Pharmaceuticals and Other Medical Technologies. Cambridge University Press, Cambridge 1995.
21. Hochberg MC, Sutton JD. Physical-disability and psychosocial dysfunction in systemic lupus erythematosus. J Rheumatol 1988; 15: 959-964.
22. Milligan SE, Hom DL, Ballou SP et al. An assessment of the Health Assessment Questionnaire functional ability index among women with systemic lupus erythematosus. J Rheumatol 1993; 20: 972-976.
23. Gladman DD, Urowitz MB, Ong A et al. A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus 1996; 5: 190-195.
24. Burckhardt CS, Archenholtz B, Bjelle A. Quality of life of women with systemic lupus erythematosus: a comparison with women with rheumatoid arthritis. J Rheumatol 1993; 20: 977-981.
25. Abu Shakra M, Mader R, Langevitz P et al. Quality of life in systemic lupus erythematosus: a controlled study. JRheumatol 1999; 26: 306-309.
26. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
27. Omdal R, Husby G, Mellgren SI. Mental health status in systemic lupus erythematosus. Scand J Rheumatol 1995; 24: 142-145.
28. Hurst NP, Kind P, Ruta D et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36: 551-559.
29. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the euroqol. Br J Rheumatol 1997; 36: 786-793.
30. Krupp LB, Larocca NG, Muir J, Steinberg AD. A study of fatigure in systemic lupus erythematosus. J Rheumatol 1990; 17: 1450-1452.
31. Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1181-1188.
32. Pistiner M, Wallace DJ, Nessim S et al. Lupus erythematosus in the 1980s survey of 570 patients. Semin Arthritis Rheum 1991; 21: 55-64.
33. Gladman DD, Urowitz MB, Gough J, MacKinnon A. Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol 1997; 24: 2145-2148.
34. Utset TO, Golden M, Siberry G et al. Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjogren's syndrome. J Rheumatol 1994; 21: 2039-2045.
35. Krupp LB, Larocca NG, Muirnash J, Steinberg AD. The fatigue severity scale - application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123.
36. Chalder T, Berelowitz G, Pawlikowska T et al. Development of a fatigue scale. J Psychosom Res 1993; 37: 147-153.
37. Thomas E, Hay EM, Hajeer A, Silman AJ. Sjogren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol 1998; 37: 1069-1076.
38. Fitzpatrick R, Ziebland S, Jenkinson C, Mowat A. A comparison of the sensitivity to change of several health status instruments in rheumatoid arthritis. J Rheumatol 1993; 20: 429-436.
39. Valladolid GR, Aguado AG, Criado AB et al. Prevalence of psychiatric disturbances and psychopathologic status in patients with systemic lupus erythematosus. Rev Clin Esp 1998; 198: 61-65.
40. Stoll T, Gordon C, Seifert B et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 1608-1614.
41. Fortin PR, Abrahamowicz M, Neville C et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998; 7: 101-107.
42. Thumboo J, Fong KY, Ng TP et al. Validation of the MOS SF-36 for quaity fo life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 1999; 26: 97-102.
43. Gladman DD, Urowitz MB, Ong A et al. Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life. Clin Exp Rheumatol 1996; 14: 305-308.
44. Stoll T, Stucki G, Malik J et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996; 55: 756-760.
45. Stoll T, Stucki G, Malik J et al. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 309-313.
46. Gordon C, Exley AR, Clay C et al. Changes in SF36 scors in SLE patients with change in disease activity measured by the BILAG index. Arthritis Rheum 197; 40: 487.
47. Taylor J, Skan J, Erb B et al. Lupus patients with fatigue: is there a link with the fibromyalgia syndrome? Arthritis Rheum 1998; 41: 1797.
48. Sutcliffe N, Clarke AE, Levinton C et al. Determinants of health status in patients with SLE. J Rheumatol 1999. In press.
49. Moore A, Petri MA, Manzi S et al. The use of alternatiave medical therapies in patients with systemic lupus erythematosus (SLE). Arthritis Rheum 1998; 41 (9 suppl): S133
50. Ramos-Remus C, Gamez-Nava JI, Gonzalez-Lopez L, Suarez-Almazor ME. Use of alternative medicine in a consecutive sample of patients with systemic lupus erythematosus (letter). J Rheumatol 1997; 24: 12
51. Clarke AE, Petri MA, Manzi S et al. An international perspective on the well-being and health care costs for patients with systemic lupus erythematosus. J Rheumatol 1999; 26: 1500-1511.
52. St Pierre Y, Penrod J, Petri M et al. Underestimating the value of rheumatic diseases: Assessing the costs of women with lupus (SLE). Arthritis Rheum 1998; 41(9): S221
53. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997; 24: 719-725.
54. Lanes SF, Lanza LL, Radensky PW et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. Arthritis Rheum 1997; 40: 1475-1481.
55. Clarke AE, Bloch DA, Danoff DS, Esdaile JM. Decreasing costs and improving outcomes in SLE: using regresson trees to develop health policy. J Rheum 1994; 21: 2246-2253.
56. Lacaille D, Clarke AE, Bloch DA et al. The impact of disease activity and disease severity on short-term costs of systemic lupus erythematosus. J Rheum 1994; 21: 448-453.
57. Gironomi G, Clarke AE, Hamilton VH et al. Why health care costs more in the US: comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal. Arthritis Rheum 1996; 39: 979-987.
58. Clarke AE, Zowall H, Levinton C et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a twelve year study. J Rheumatol 1997; 24: 1051-1060.
59. Clarke AE, Levinton C, Joseph L et al. Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1068-1075.
60. Clarke AE. Arthritis patient education: How economic evaluations can inform health policy. Can J Aging 1997;Suppl: 162-176.
61. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol 1996; 23: 47-51.
62. Van Jaaarsveld CHM, Jacobs JWG, Schrijvers AJP et al. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Theumatol 1998; 37: 837-847.
63. Meenan RF, Yelin EH, Henke CJ et al. The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1978; 21: 827-833.
64. Finn D, Allen P, Hoffstein P et al. Economic costs of systemic lupus erythematosus: a five year prospective study. Arthritis Rheum 1993; 36(9 Suppl); S192.
65. Lubeck DP, Spitz PW, Fries JF et al. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986; 29: 488-493.
66. Liang MH, Larson M, Thompson M et al. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984; 27: 522-529.
67. Yelin E, Henke CJ, Epstein WV. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 1987; 30: 507-512.
68. Allaire SH, Meenan RF, Anderson JJ. The impact of rheumatoid arthritis on the household work performance of women. Arthritis Rheum 1991; 34: 669-678.
69. Felts W, Yelin E. The economic impact of the rheumatic diseases in the United States. J Rheumatol 1989; 16: 867-884.
70. Yelin E, Callahan LF, for the National Arthritis Data Work Group. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995; 38: 1351-1362.
71. Badley EM, Rasooly I, Webster GK. Relative importance of musculoskeletal disorders as a cause of chronic health problems, disability, and health care utilization: findings from the 1990 Ontario Health Survey. J Rheumatol 1994; 21: 505-514.
72. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 127-134.
73. Jacobs J, Keyserling JA, Britton M et al. The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: the medical program. J Clin Epidemiol 1988; 41: 215-223.
74. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35: 781-790.
75. Finkler SA. The distinction between costs and charges. Ann Intern Med 1982; 96: 102-109.
76. Canadian Coordinating Office for Health Technology. Assessment Guidelines for Economic Evaluation of Pharmaceuticals. Ontario. Canadian Coordinating Office for Health Technology Assessment: Ottawa 2nd edition: 1997; pp 1-85.
77. Baladi J-F. A Guidance Document for the Costing Process. Ontario. Canadian Coordinating Office for Health Technology Assessment: Ottawa 1996.
78. Cain G. The Economic Analysis of Labor Market Discrimination: A Survey. In: Ashenfelter OC and Layard R (eds). Handbook of Labor Economics. Elsevier Science; Amsterdam 1986 pp 693-785.
79. McCarthy S and Sallot J. Pay equity bill at least $3-billion. The Globe and Mail July 30, 1998.
80. Goldin C. Understanding the Gender Gap: An Economic History of American Women. Oxford University Press: New York 1990.
81. Koopmanschap MA, Rutten FFH, Van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econom 1995; 14: 171-189.
82. Earnings of Men and Women, 1995. Statistics Canada: Ottawa 1997; 13-217.
83. Households' Unpaid Work: Measurement and Valuation. 13-603E. Statistics Canada, Minister of Industry: Ottawa 1995.
84. Jackson C. The Value of Household Work in Canada, 1986. Canadian Economic Ohserver U-010. Statistics Canada, Minister of Industry, Ottawa 1992.
85. McInnes PM, Schuttinga J, Sanslone WR et al. The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide. Arthritis Rheum 1994; 37: 1000-1006.